人二倍体细胞是WHO认可的更安全的疫苗生产用细胞基质，已成为全世界疫苗生产首选的细胞基质。我国自主研制的二倍体细胞KMB17株和2BS株来源于人胚肺细胞，因其无致癌性、无外源因子污染，且细胞性状比较稳定，越来越多地在人用疫苗研发与生产中使用。由于KMB17细胞和2BS细胞对多种病毒具有敏感性，因此也作为细胞基质被应用于许多病毒性疫苗的研究开发。目前，用这两种人二倍体细胞生产的疫苗，包括甲型肝炎疫苗、脊髓灰质炎疫苗和肠道病毒71型灭活疫苗等，已在我国大量上市。

Human diploid cells are the cell matrix for safer vaccine production approved by WHO, and have become the first choice for vaccine production in the world. The diploid KMB17 and 2BS strains independently developed in China are derived from human embryonic lung cells, They have no carcinogenicity, no exogenous factor pollution and relatively stable cell characteristics, more use in human vaccine development and production. Since KMB17 cells and 2BS cells are sensitive to a variety of viruses, they have also been used as cell substrates in the development of many viral vaccines. The vaccines produced by these two kinds of human diploid cells have been widely marketed in China, including hepatitis A vaccine, poliovirus vaccine and inactivated enterovirus 71 vaccine.